TABLE 1:

In vitro CRM1 binding affinity and in vivo activity of NESs.

		RC/N 95% confidence interval			Kd 95% confidence interval
NES	Mean RC/N	Low	High	Kd (nM)	Low	High
PKI	1.37	1.33	1.41	34b	25	46
CPEB4	1.20	1.13	1.27	800b	500	1200
MEK1a	1.17	1.11	1.23	70	40	130
ADAR1a	0.85	0.75	0.96	69	49	96
hRio2	0.82	0.72	0.92	2800b	1700	4700
FMRP	0.81	0.76	0.86	2000	1200	3400
Super PKIa	0.80	0.64	0.96	4	Uc	12
X11L2	0.79	0.71	0.87	1500	900	2300
NPMmutA	0.72	0.61	0.83	790	640	980
HIV Reva	0.70	0.62	0.77	1180	990	1400
Pax	0.60	0.49	0.70	700	400	1000
mDia2	0.59	0.52	0.66	1600	1000	2700
CPEB4-R	0.59	0.50	0.67	710b	560	880
p73a	0.59	0.53	0.65	2000	1700	2400
HDAC5	0.54	0.48	0.60	1600	1100	2400
SMAD4	0.44	0.37	0.51	4600	3600	5900
MVM NS2a	0.38	0.30	0.45	2	Uc	9
hRio2-R	0.36	0.30	0.43	2600b	2000	3300
HPV E7a	0.29	0.24	0.33	34,000	22,000	53,000
CDC7	0.21	0.16	0.26	20,000	15,000	27,000
Stradαa	0.19	0.13	0.26	10,300	8000	13,000
SNUPN	0.16	0.12	0.20	12,500b	10,000	15,000
PKI (I47A)	0.03	0.02	0.04	150,000	90,000	310,000
PKI (L42A/L45A)a	0.01	0.00	0.02	900,000	300,000	Uc

^aBinding affinities measured in this study. Others were measured in our previous studies and reanalyzed to obtain 95% confidence interval.

^bK_d reported here are slightly different from before as all data are now fitted using averages of triplicate experiments without weighted fitting. The absolute numbers are only slightly different from previously reported and differences are insignificant.

^cU, cannot be defined.